Update - Evusheld no longer authorized in the U.S.
January 26, 2023 - FDA revised its emergency use authorization (EUA) for Evusheld to limit its use to areas where more than 10% of circulating COVID-19 variants are known to be susceptible to it. Across the U.S., CDC data shows that such strains are less than 10% of those currently circulating, so Evusheld is not authorized until further notice.
Read MoreSon with chronic granulomatous disease goes through BMT with family’s support
Kathi and Rick Narlock have advocated for their son Nick Narlock since infancy when he was diagnosed with chronic granulomatous disease (CGD) and supported him as he underwent a bone marrow transplant (BMT) treatment.
Read MoreIDF serves thousands through education, advocacy, and research efforts
In 2022, IDF’s programs and resources reached thousands of individuals in the primary immunodeficiency community and furthered advocacy and research goals.
Read MoreMedicare Home IVIG Benefit: FAQs
As the Medicare home IVIG demonstration project winds down with the new, permanent benefit starting January 1, 2024, here are answers to some frequently asked questions about the transition.
Read MoreMom’s common variable immune deficiency diagnosis explains lifelong infections and fatigue
Susan Day’s diagnosis of common variable immune deficiency (CVID) at 41 helped explain the infections and fatigue she experienced since childhood and led to the testing of her children, who also have primary immunodeficiency (PI).
Read More
